Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.5K Sell
292
-85
-23% -$18.9K 0.03% 149
2025
Q4
$86.1K Sell
377
-115
-23% -$26.2K 0.03% 153
2025
Q3
$114K Buy
+492
New +$100K 0.04% 147
2025
Q2
Sell
-6,802
Closed -$1.43M 146
2025
Q1
$1.43M Sell
6,802
-1,342
-16% -$261K 0.39% 93
2024
Q4
$1.45M Buy
8,144
+904
+12% +$166K 0.4% 92
2024
Q3
$1.43M Sell
7,240
-879
-11% -$164K 0.38% 113
2024
Q2
$1.39M Buy
8,119
+345
+4% +$57.1K 0.39% 90
2024
Q1
$1.42M Sell
7,774
-1,756
-18% -$303K 0.34% 91
2023
Q4
$1.48M Buy
9,530
+307
+3% +$44.8K 0.35% 81
2023
Q3
$1.37M Buy
9,223
+8,115
+732% +$1.19M 0.35% 78
2023
Q2
$149K Sell
1,108
-230
-17% -$33.7K 0.04% 281
2023
Q1
$213K Buy
1,338
+217
+19% +$33.2K 0.07% 209
2022
Q4
$181K Buy
+1,121
New +$172K 0.06% 200
2022
Q3
Sell
-1,813
Closed -$278K 203
2022
Q2
$278K Sell
1,813
-595
-25% -$90.9K 0.1% 190
2022
Q1
$390K Sell
2,408
-1,627
-40% -$236K 0.16% 101
2021
Q4
$546K Buy
+4,035
New +$477K 0.13% 108
2021
Q3
Sell
-4,628
Closed -$521K 100
2021
Q2
$521K Buy
4,628
+1,120
+32% +$126K 0.16% 116
2021
Q1
$380K Buy
+3,508
New +$375K 0.14% 123

Other funds holding ABBV

AXS Investments's ABBV Position: Q1 2026 in Review

AXS Investments reduced its AbbVie (ABBV) stake by 23% in Q1 2026, selling an estimated $18.9K and leaving 292 shares worth $63.5K. The position accounts for 0.03% of the portfolio, ranked #149.

AXS Investments first reported a position in ABBV in Q1 2021 and has held it in 18 quarters since. The position peaked at $1.48M in Q4 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • AXS Investments held 292 shares of AbbVie worth $63.5K as of Q1 2026.
  • AXS Investments sold 85 AbbVie shares in Q1 2026, an estimated $18.9K.
  • AbbVie made up 0.03% of AXS Investments's portfolio in Q1 2026, its #149 holding.
  • AXS Investments first reported a position in AbbVie in Q1 2021 and has held it in 18 quarters since.
  • AXS Investments's AbbVie position peaked at $1.48M in Q4 2023.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on AXS Investments's 13F filing for Q1 2026, filed 6 May 2026.